Noninfectious Uveitis

  The FDA approved an expanded label for Iluvien, which is now indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye, according to a press release from ANI Pharmaceuticals.

In this Healio Video Perspective from the Retina Society meeting, Steven Yeh, MD, of Stanley M. Truhlsen Eye Institute, discusses Xipere for the treatment of noninfectious uveitis-associated macular edema.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Tom Mitro about his career and impact in ophthalmology.

Alimera Sciences acquired the U.S. commercialization rights for Yutiq, a treatment for chronic noninfectious uveitis affecting the posterior segment, from EyePoint Pharmaceuticals, according to a press release.

Higher anti-drug antibody levels were associated with an increased risk for tumor necrosis factor inhibitor treatment failure in patients with noninfectious uveitis who received adalimumab, according to a study.

China’s Center for Drug Evaluation of the National Medical Products Administration approved Yutiq for chronic noninfectious uveitis affecting the posterior segment, EyePoint Pharmaceuticals and OcuMension announced in a press release.

Patients with infectious uveitis are at an increased risk for corneal graft failure compared with patients with noninfectious uveitis, according to a study published in Cornea.

The goal of therapy for noninfectious uveitis is to control inflammation while minimizing sequelae and side effects, according to one presenter at OSN New York Retina.

At the virtual Euretina meeting, Quan Dong Nguyen, MD, discusses local therapies for noninfectious uveitis, an approach that avoids the side effects of systemic treatment.

Patients with noninfectious uveitis affecting the posterior segment who were treated with a fluocinolone acetonide intravitreal implant experienced beneficial effects on macular edema through 36 months.